Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;32(9):2153-2158.
doi: 10.1681/ASN.2021040490. Epub 2021 Jun 16.

Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

Clément Danthu  1   2 , Sébastien Hantz  2   3 , Arthur Dahlem  1 , Marion Duval  1 , Bacary Ba  1 , Manon Guibbert  3 , Zhour El Ouafi  1 , Séverine Ponsard  1 , Insaf Berrahal  1 , Jean-Michel Achard  1 , Frédérique Bocquentin  1 , Vincent Allot  1 , Jean-Philippe Rerolle  1 , Sophie Alain  2   3 , Fatouma Touré  1   4
Affiliations

Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

Clément Danthu et al. J Am Soc Nephrol. 2021 Sep.

Abstract

Background: Kidney transplant recipients and patients receiving hemodialysis are immunocompromised populations that are prioritized for COVID-19 vaccination but were excluded from clinical trials of SARS-CoV-2 mRNA vaccines. Antibody titers and rates of seroconversion after vaccination are lower among patients with CKD and those taking immunosuppressants compared with controls. Data are lacking regarding their humoral response to vaccination to prevent COVID-19.

Methods: This investigation of early serological response after COVID-19 vaccination with the Pfizer/BioNTech (BNT162b2) mRNA vaccine included 78 patients undergoing hemodialysis, 74 kidney transplant recipients, and seven healthy controls. We recorded data from the medical file for various clinical parameters, including response to hepatitis B vaccination, and measured antibody titers against SARS-CoV-2 at 0, 14, 28, 36, and 58 days after the first injection.

Results: In controls, we detected antibodies at a positive level (>13 arbitrary units per ml; AU/ml) at day 14 postinjection, which increased progressively to peak at day 36 (1082 AU/ml; interquartile range [IQR], 735.0-1662.0). Patients undergoing hemodialysis had lower titers that peaked at day 58 (276 AU/ml; IQR, 83.4-526.0). We detected a positive antibody level in only three transplant recipients at day 36. In patients on hemodialysis, those aged <75 years had a higher antibody response versus those aged >75 years, and serum albumin and Kt/V were positively correlated with serological response (P<0.04 and P<0.0, respectively); nonresponders to HBV vaccine had the lowest anti-SARS-CoV-2 antibody titers.

Conclusions: Our results suggest that the postvaccination humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients, and is reduced by the uremic condition in patients undergoing hemodialysis.

Keywords: COVID-19; hemodialyzed; humoral response; kidney transplant recipients; kinetic; vaccine.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Kinetics of humoral response to anti–COVID-19 vaccination in kidney transplant recipients, patients undergoing hemodialysis, and healthy controls. Course of SARS-CoV-2 IgG antispike antibody titers for each patient at 14, 28, 36, and 58 days after the first injection of vaccine (median and IQR range). Cutoff for detection was a titer >1.85 AU/ml, and the cutoff for positive serology was defined according to the manufacturer’s instructions as a titer >13 AU/ml.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kronbichler A, Anders HJ, Fernandez-Juárez GM, Floege J, Goumenos D, Segelmark M, et al. .; Immunonephrology Working Group of the ERA-EDTA (European Renal Association – European Dialysis, Transplant Association): Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases [published online ahead of print March 9, 2021]. Nephrol Dial Transplant - PMC - PubMed
    1. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. .: Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 383: 2439–2450, 2020 - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. .; C4591001 Clinical Trial Group: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383: 2603–2615, 2020 - PMC - PubMed
    1. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. .: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586: 589–593, 2020 - PubMed
    1. Krueger KM, Ison MG, Ghossein C: Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. Am J Kidney Dis 75: 417–425, 2020 - PubMed

MeSH terms